Skip to content

Quartet™ Bad Oeynhausen Trial

Quartet™ Bad Oeynhausen Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01850264
Acronym
QUOTA
Enrollment
81
Registered
2013-05-09
Start date
2013-03-31
Completion date
2018-12-31
Last updated
2019-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Resynchronization Therapy, Congestive Heart Failure

Keywords

cardiac resynchronization therapy; heart failure, congestive

Brief summary

Primary objective of this study is to evaluate whether the use of a quadripolar left ventricular (LV) electrode compared to a standard bipolar LV electrode leads to lower non-responder rates in patients undergoing cardiac resynchronization therapy (CRT)

Interventions

DEVICEApplication of quadripolar / bipolar LV electrodes

Sponsors

Heart and Diabetes Center North-Rhine Westfalia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Indication for CRT-D implantation according to current guidelines * Ischemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) * Sinus rhythm * NYHA II-IV * Age ≥ 18 years * Written informed consent to participate in the study

Exclusion criteria

* Right bundle brunch block * Valvular cardiomyopathy * Patient receiving a non-transvenous LV electrode * Known pregnancy * Age \< 18 years * Life expectancy \< 1 year * Atrial fibrillation / atrial flutter at the time of enrolment * Inability to provide informed consent * Participation in another study with active therapeutic arm * Regular follow-up in the study center within the first 6 months after implantation not guaranteed

Design outcomes

Primary

MeasureTime frame
Increase in peak oxygen consumption6 months
Reduction of New York Heart Association (NYHA) functional class6 months
Survival6 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026